Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Cancer-associated fibroblasts (CAFs) play an important role in metastatic melanoma, and an enhanced understanding of that role could lead to important new therapeutic pathways, according to a new ...

expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications ...

Iovance Biotherapeutics plans to add hundreds of new jobs at the Navy Yard in South Philadelphia as part of an effort to ramp ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

Theratechnologies Inc.’s THTX share price has surged by 28.57%, which has investors questioning if this is right time to sell ...

The stock is down by 74% over the trailing-12-month period and, at under $4 per share, is barely above its 52-week low. Still ...

BioAtla (NASDAQ:BCAB – Get Free Report) is anticipated to announce its quarterly earnings results after the market closes on ...

The lead Eikon drug, EIK1001, is a small molecule designed to hit toll ... and a placebo as a first-line treatment for advanced melanoma. The trial’s targeted enrollment is 740 patients.